Ritedose Releases Two New Single-Dose Syringe Products to the Market: Glycopyrrolate Injection 0.6 mg/3 mL (0.2 mg/mL) and Glycopyrrolate Injection 1 mg/5 mL (0.2 mg/mL)

COLUMBIA, S.C. (April 16, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, launched two new unit dose syringe products, Glycopyrrolate Injection 0.6 mg/3 mL (0.2 mg/mL) and Glycopyrrolate Injection 1 mg/5 mL (0.2 mg/mL). These are part of a 12-product rollout expected from Ritedose over the next six months for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.

Both with anticipated Beyond Use Dates (BUDs) of 150 days, the single-dose syringes of Glycopyrrolate Injection 0.6 mg/3 mL (0.2 mg/mL) and Glycopyrrolate Injection 1 mg/5 mL (0.2 mg/mL) can be stored at room temperature and are already diluted, labeled with cautionary statements, color-coded to ASTM drug class standards, and ready to be administered within OR and acute care settings. The standardized concentrations in prefilled syringes negate the need for in-hospital compounding and help decrease the possibility of sub or supra therapeutic doses for patients. Ritedose is offering Glycopyrrolate Injection in multiple per/mL concentrations and fill volumes to meet varied clinical patient needs, as well as to provide clinicians choice in what they prescribe.

“Ritedose serves as the missing link for our hospital clients in the supply chain disruptions they often experience,” said Jody Chastain, Ritedose president and CEO. “Our competitive pricing and outsourcing model can make a significant difference in efficiency for hospitals.”

Founded in 1995 in Columbia, South Carolina, The Ritedose Corporation is an industry leader in the aseptic manufacturing and liquid packaging of respiratory inhalation products, and utilizes proven Blow-Fill-Seal (BFS) equipment and processes to ensure efficient, consistent and safe dosage delivery. The company’s 25-year track record includes the delivery of more than 8 billion doses since 2012 without a single recall, and its current capacity is 1.7 billion units annually. In 2020, The Ritedose Corporation was selected as a subcontractor to ApiJect for the production of single-dose prefilled syringes intended for administering COVID-19 vaccines.

To learn more about all Ritedose products view the product catalog, or contact us for ordering information.

- - -